- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim, September 12, 2018 – Bayer Animal Health GmbH and NeuroCycle Therapeutics, Inc. (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed and controlled by NCT. Further terms of the agreement have not been disclosed.
Pet ownership is growing around the world and with that customers’ requirement for more effective and convenient treatment options. “At Bayer, we are committed to help pet owners improve the health and well-being of their animals,” said Dr. Sabine Bongaerts, Head of Development within Bayer Animal Health. “We know that allergies are among the most important health and well-being concerns for pet owners and veterinarians. The license agreement with NCT is a strong signal of our commitment to our customers around the world to address these concerns.”
Dr. Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, added: “Today’s agreement underlines our strategy to combine the know-how from creative start-up companies like NCT with opportunities derived from Bayer’s research. It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector. Now, we will focus on evolving these options from research and development to market maturity.”
Dr. Jed Hubbs, NeuroCycle Therapeutics’ CEO added: “Our goal is to maximize the humanitarian impact of our innovative technologies. This license agreement with Bayer Animal Health aligns with this goal by allowing our technology to be applied beyond our core focus on human health.”
About Neurocycle Therapeutics
NeuroCycle Therapeutics, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule drugs that target the central nervous system. The company is currently developing novel treatments of atopic dermatitis and other highly pruritic indications, orphan epilepsies, and chronic pain.
For more information, please visit https://neurocycletherapeutics.com
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.
Find more information at http://animalhealth.bayer.com
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center